2011
DOI: 10.1177/0883073811401395
|View full text |Cite
|
Sign up to set email alerts
|

A Claim For Caution in the Use of Promising Bumetanide to Treat Neonatal Seizures

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 11 publications
0
3
0
Order By: Relevance
“…Interestingly, due to its ability to inhibit the brain-specific transporter NKCC1, bumetanide has been proposed as a promising candidate to treat brain diseases 46 , based on studies in animal models 12, 34, 46 and recent clinical trials 46-48 . However, the use of this drug in neonates has been partially questioned 10, 49-50 due to the key role played by depolarizing GABA during early development 8 . Our data similarly suggest possible long-term consequences of NKCC1 inhibition during early development.…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, due to its ability to inhibit the brain-specific transporter NKCC1, bumetanide has been proposed as a promising candidate to treat brain diseases 46 , based on studies in animal models 12, 34, 46 and recent clinical trials 46-48 . However, the use of this drug in neonates has been partially questioned 10, 49-50 due to the key role played by depolarizing GABA during early development 8 . Our data similarly suggest possible long-term consequences of NKCC1 inhibition during early development.…”
Section: Discussionmentioning
confidence: 99%
“…As mentioned above, NKCC1 has an age-dependent expression in SNR and hippocampus. While the effects of bumetanide on seizures need to be interpreted cautiously (Vanhatalo et al, 2009; Chabwine and Vanden Eijnden, 2011), it would be worth testing also the effects of loop diuretic drugs into the SNR to assess their potential age- and sex-related role in SNR-mediated epilepsy modulation.…”
Section: Discussionmentioning
confidence: 99%
“…A single clinical study showed reduction in seizure frequency and duration following bumetanide treatment [90]. Though promising as an add-on agent for neonatal seizures, the potential for adverse effects such as ototoxicity, and partial central nervous system bioavailability may ultimately limit the utility of bumetanide [91]. …”
Section: Pharmacologic Strategiesmentioning
confidence: 99%